149 related articles for article (PubMed ID: 3319648)
1. Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion.
Sartor G; Ursing D; Nilsson-Ehle P; Wåhlin-Boll E; Melander A
Eur J Clin Pharmacol; 1987; 33(3):279-82. PubMed ID: 3319648
[TBL] [Abstract][Full Text] [Related]
2. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Simpson HC; Sturley R; Stirling CA; Reckless JP
Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
[TBL] [Abstract][Full Text] [Related]
4. Effect of glipizide treatment on various aspects of glucose, insulin, and lipid metabolism in patients with noninsulin-dependent diabetes mellitus.
Reaven GM
Am J Med; 1983 Nov; 75(5B):8-14. PubMed ID: 6369970
[TBL] [Abstract][Full Text] [Related]
5. Propranolol does not inhibit sulphonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus.
Groop L; Tötterman KJ
Acta Endocrinol (Copenh); 1982 Jul; 100(3):410-5. PubMed ID: 7051722
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.
Groop L; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
Diabetes Care; 1987; 10(6):671-8. PubMed ID: 3123184
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
8. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
Scheen AJ; Lefebvre PJ; Luyckx AS
Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
[TBL] [Abstract][Full Text] [Related]
9. Extrapancreatic effects of a sulphonylurea. Decrease in xylose absorption by glipizide in type II diabetics.
Kollind M; Adamson U; Lins PE; Ohlsén P
Acta Med Scand; 1984; 215(5):443-5. PubMed ID: 6377829
[TBL] [Abstract][Full Text] [Related]
10. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
Ahrén B; Lundquist I; Scherstén B
Diabetes Res; 1986 Jul; 3(6):293-300. PubMed ID: 3530592
[TBL] [Abstract][Full Text] [Related]
11. Insulin and sulphonylurea in the therapy of type 2 diabetes.
Sotaniemi EA; Vierimaa E; Huupponen R; Karvonen I; Vuoti MJ; Rytömaa K
Diabetes Res Clin Pract; 1990 Mar; 8(3):243-51. PubMed ID: 2111239
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term insulin therapy upon therapeutic response to glipizide.
Schwartz SL; Fischer JS; Kipnes MS; Boyle M
Am J Med; 1987 Sep; 83(3A):22-30. PubMed ID: 3307403
[TBL] [Abstract][Full Text] [Related]
13. Effect of sulfonylurea on glucose, insulin and C-peptide responses to a meal stimulus in a patient with type 2 diabetes and liver disease.
Ahrén B; Scherstén B
Acta Med Scand; 1984; 215(5):487-91. PubMed ID: 6430037
[TBL] [Abstract][Full Text] [Related]
14. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study.
Groop LC; Ratheiser K; Luzi L; Melander A; Simonson DC; Petrides A; Bonadonna RC; Widén E; DeFronzo RA
Acta Diabetol; 1991; 28(2):162-8. PubMed ID: 1777653
[TBL] [Abstract][Full Text] [Related]
15. The effect of glipizide on HDL and HDL subclasses.
Bergman M; Gidez LI; Eder HA
Diabetes Res; 1986 Jun; 3(5):245-8. PubMed ID: 3742945
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.
Osei K; Rhinesmith S; Gaillard T; Schuster D
Metabolism; 2003 May; 52(5):565-72. PubMed ID: 12759885
[TBL] [Abstract][Full Text] [Related]
17. Effect of glipizide on insulin secretion and insulin metabolism in obese type II diabetic patients.
Bonora E; Pisani F; Micciolo R; Corgnati A; Muggeo M
Diabetes Care; 1987; 10(6):687-91. PubMed ID: 3322723
[TBL] [Abstract][Full Text] [Related]
18. Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM.
Jeppesen J; Zhou MY; Chen YD; Reaven GM
Diabetologia; 1994 Aug; 37(8):781-7. PubMed ID: 7988780
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of action of sulfonylureas at the pancreatic and extra-pancreatic levels in prolonged treatment in noninsulin-dependent diabetic patients].
Serrano Ríos M; Ordoñez Pérez AJ; Sánchez Arriarán MS; Villalba Díaz MT; Nash Raina RE; de la Viña S
Rev Clin Esp; 1983 Dec; 171(6):385-90. PubMed ID: 6369443
[No Abstract] [Full Text] [Related]
20. Influence of sulfonylureas on the secretion, disposal and effect of insulin.
Almér LO; Johansson E; Melander A; Wåhlin-Boll E
Eur J Clin Pharmacol; 1982; 22(1):27-32. PubMed ID: 7047169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
